Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in ...

Johnson & Johnson (JNJ) announced that its subsidiary, Red River Talc LLC, has voluntarily filed for a prepackaged Chapter 11 ...

September is Ovarian Cancer Awareness Month, focusing on raising awareness, improving early detection, and supporting ...

Attorneys representing tens of thousands of women with ovarian cancer linked to use of Johnson & Johnson (NYSE:JNJ) talc products say they will im ...

September is recognized as Ovarian Cancer Awareness Month. But, do you know the signs and symptoms that could be impacting ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Red River Talc, a Johnson & Johnson subsidiary, filed for Chapter 11 bankruptcy to settle ovarian cancer claims with an $8B ...

J&J's proposed settlement would pay talc claimants about $10 billion over 25 years. The present value of the settlement is ...

Johnson & Johnson said it received overwhelming support for a roughly $8 billion settlement of claims that its talc-based ...